Aratana Therapeutics Inc (fka PETX)

[biotech_researcher]

Blue, I review Aratana’s PR, and your post is a little off. Only $3.1 million of actual revenue was booked in Q2. $1.9 million was licensing and collaboration. Organic sales dropped much worse..

“In the second quarter of 2018, the Company recognized $1.8 million in net product sales of NOCITA, $1.3 million in net product sales of ENTYCE and $1.9 million in licensing and collaboration revenue from Elanco for GALLIPRANT.”